BetterScholar BetterScholar
9
Role
Title
Level Year L/R
🐜 Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus
8 auth. G. Ruiz‐Irastorza, M. Egurbide, J. Pijoan, M. Garmendia, I. Villar, A. Martínez-Berriotxoa, ... J. Erdozain, C. Aguirre
8 2006
8
🐜
🐜 Prednisone in lupus nephritis: how much is enough?
7 auth. G. Ruiz‐Irastorza, Á. Danza, I. Perales, I. Villar, M. García, S. Delgado, ... M. Khamashta
6 2014
6
🐜
🐜 Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus
7 auth. A. Martínez-Berriotxoa, G. Ruiz‐Irastorza, M. Egurbide, M. Garmendia, Jose Gabriel Erdozain, I. Villar, ... C. Aguirre
6 2007
6
🐜
🐬 Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy.
G. Ruiz‐Irastorza, M. Garmendia, I. Villar, M. Egurbide, C. Aguirre
6 2013
6
🐬
🐜 Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis
13 auth. J. Hernández-Rodríguez, G. Murgia, I. Villar, E. Campo, S. Mackie, A. Chakrabarty, E. Hensor, A. Morgan, C. Font, S. Prieto-González, ... G. Espígol-Frigolé, J. Grau, M. Cid
5 2016
5
🐜
🐬 Correction of Allopurinol Dosing Should Be Based on Clearance of Creatinine, but Not Plasma Creatinine Levels: Another Insight to Allopurinol-Related Toxicity
F. Pérez-Ruiz, I. Hernando, I. Villar, J. Nolla
5 2005
5
🐬
🐬 Peripheral Arterial Disease in Systemic Lupus Erythematosus: Prevalence and Risk Factors
J. Erdozain, I. Villar, J. Nieto, G. Ruiz‐Irastorza
5 2014
5
🐬
🐜 LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
8 auth. Eguzkine Ochoa, M. Iriondo, C. Manzano, A. Fullaondo, I. Villar, G. Ruiz‐Irastorza, ... A. Zubiaga, A. Estonba
4 2016
4
🐜
🐬 Predictors of peripheral arterial disease in SLE change with patient’s age
J. Erdozain, I. Villar, J. Nieto, I. Ruiz-Arruza, G. Ruiz‐Irastorza
2 2017
2
🐬